Tibet AIM Pharm. Inc.

SZSE:002826 Stock Report

Market Cap: CN¥2.0b

Tibet AIM Pharm Past Earnings Performance

Past criteria checks 2/6

Tibet AIM Pharm has been growing earnings at an average annual rate of 0.1%, while the Pharmaceuticals industry saw earnings growing at 9.1% annually. Revenues have been growing at an average rate of 5.7% per year. Tibet AIM Pharm's return on equity is 4.6%, and it has net margins of 5.2%.

Key information

0.1%

Earnings growth rate

-0.4%

EPS growth rate

Pharmaceuticals Industry Growth10.9%
Revenue growth rate5.7%
Return on equity4.6%
Net Margin5.2%
Next Earnings Update25 Apr 2025

Recent past performance updates

Investors Can Find Comfort In Tibet AIM Pharm's (SZSE:002826) Earnings Quality

Nov 06
Investors Can Find Comfort In Tibet AIM Pharm's (SZSE:002826) Earnings Quality

Recent updates

Tibet AIM Pharm. Inc.'s (SZSE:002826) Popularity With Investors Under Threat As Stock Sinks 27%

Jan 10
Tibet AIM Pharm. Inc.'s (SZSE:002826) Popularity With Investors Under Threat As Stock Sinks 27%

What Tibet AIM Pharm. Inc.'s (SZSE:002826) 28% Share Price Gain Is Not Telling You

Nov 26
What Tibet AIM Pharm. Inc.'s (SZSE:002826) 28% Share Price Gain Is Not Telling You

Investors Can Find Comfort In Tibet AIM Pharm's (SZSE:002826) Earnings Quality

Nov 06
Investors Can Find Comfort In Tibet AIM Pharm's (SZSE:002826) Earnings Quality

Some Confidence Is Lacking In Tibet AIM Pharm. Inc.'s (SZSE:002826) P/E

Jun 07
Some Confidence Is Lacking In Tibet AIM Pharm. Inc.'s (SZSE:002826) P/E

Investors Can Find Comfort In Tibet AIM Pharm's (SZSE:002826) Earnings Quality

May 02
Investors Can Find Comfort In Tibet AIM Pharm's (SZSE:002826) Earnings Quality

Risks Still Elevated At These Prices As Tibet AIM Pharm. Inc. (SZSE:002826) Shares Dive 26%

Feb 29
Risks Still Elevated At These Prices As Tibet AIM Pharm. Inc. (SZSE:002826) Shares Dive 26%

Revenue & Expenses Breakdown

How Tibet AIM Pharm makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

SZSE:002826 Revenue, expenses and earnings (CNY Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 246423336214
30 Jun 246434135415
31 Mar 246563531813
31 Dec 236671529114
30 Sep 238034732722
30 Jun 238474631617
31 Mar 238424432013
01 Jan 238574432513
30 Sep 22799472888
30 Jun 22772442689
31 Mar 22754462407
01 Jan 227254221711
30 Sep 217174120211
30 Jun 216933820111
31 Mar 216654019711
31 Dec 20603411787
30 Sep 20609391765
30 Jun 20573391655
31 Mar 20543371505
31 Dec 19553371475
30 Sep 19500305216
30 Jun 19502226414
31 Mar 195042610514
31 Dec 184892513316
30 Sep 18451382454
30 Jun 18408552327
31 Mar 18393612217
31 Dec 17380602174
30 Sep 17406532372
30 Jun 17441522620
31 Mar 17476562790
31 Dec 16452552590
31 Dec 15347501900
31 Dec 14291321520

Quality Earnings: 002826 has high quality earnings.

Growing Profit Margin: 002826's current net profit margins (5.2%) are lower than last year (5.8%).

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: 002826's earnings have grown by 0.1% per year over the past 5 years.

Accelerating Growth: 002826's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: 002826 had negative earnings growth (-28.8%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (-2.5%).

Return on Equity

High ROE: 002826's Return on Equity (4.6%) is considered low.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/02/01 08:53
End of Day Share Price 2025/01/27 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Tibet AIM Pharm. Inc. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution